Inactive Instrument

Mylan N.V. Nasdaq

MYL

NL0011031208

Mylan : to Host Investor Day on April 11, 2018, in New York City

March 21, 2018 at 07:31 am EDT

HERTFORDSHIRE, England and PITTSBURGH, March 21, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that it will host an Investor Day on April 11, 2018, in New York City. Mylan CEO Heather Bresch and the company's senior leadership team will showcase how Mylan is Built to Last through a deep dive into the durability of its unique diversified portfolio and pipeline, robust scientific capabilities, and one-of-a-kind commercial and operational platforms.

The presentations will be broadcasted live via webcast beginning at 1 p.m. ET and are expected to conclude by 4 p.m. ET. In-person attendance is by invitation only.

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's website at investor.mylan.com. In addition to the webcast, U.S. callers can access the event, in listen-only mode, at 800.514.4861 or 678.809.2405 for international callers (ID#7597227). A replay of the webcast also will be available following the live presentation and can be accessed on the website.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

Mylan (PRNewsfoto/Mylan N.V.)

View original content with multimedia:http://www.prnewswire.com/news-releases/mylan-to-host-investor-day-on-april-11-2018-in-new-york-city-300617280.html

SOURCE Mylan N.V.

Latest news about Mylan N.V.

Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	Apr. 18	MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	Apr. 18	MT
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	Apr. 15	MT
Viatris Inc. Appoints Corinne Le Goff as Chief Commercial Officer	Apr. 15	CI
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15	CI
Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11	CI
UK's Theramex sees no impact to HRT products supply after CMA probe	Apr. 05	RE
UK Regulator Finds Competition Concerns in Theramex-Viatris Merger Deal	Apr. 04	MT
UK watchdog says Theramex-Viatris deal raises competition concerns	Apr. 04	RE
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent	Apr. 01	RE
Viatris Launches of Ryzumvi Eye Drops to Reverse Dilation in US	Apr. 01	MT
Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States	Apr. 01	CI
Viatris Seeks M&A	Mar. 27	CI
Transcript : Viatris Inc. - Special Call	Mar. 27
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	Mar. 25	MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod	Mar. 18	MT
Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc..	Mar. 11	CI
Global markets live: 3M Company, Bayer, Apple, Boeing, Nvidia...	Mar. 11
Are good times already over?	Mar. 11
Viatris Says Mapi Pharma Receives FDA Complete Response Letter on Potential Multiple Sclerosis Drug	Mar. 11	MT
US FDA declines to approve Viatris's injection for multiple sclerosis	Mar. 11	RE
Viatris Insider Sold Shares Worth $1,005,609, According to a Recent SEC Filing	Mar. 06	MT

Chart Mylan N.V.

Duration

Period

More charts

Company Profile

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Companyâs ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.58%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+2.96%	211B
NOVARTIS AG	-0.41%	203B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals